english.prescrire.org > Spotlight > "Spotlight"
"Spotlight"

In the May issue of Prescrire International: Dulaglutide (Trulicity°) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

FREE DOWNLOADIn patients with type 2 diabetes who had a modest elevation of HbA1c, a recent trial suggested that addition of dulaglutide to hypoglycaemic therapy slightly reduced the risk of stroke, but did not reduce either all-cause mortality or cardiovascular mortality.
Full text available for free download.

Summary

  • In a randomised, placebo-controlled trial including about 10 000 patients with type 2 diabetes and a mean HbA1c of 7.3% at enrolment, addition of dulaglutide to their usual hypoglycaemic therapy did not reduce all-cause or cardiovascular mortality after a follow-up of about 5 years.
     
  • The increased risk of acute pancreatitis and pancreatic or thyroid cancer must be taken into account, as with any GLP-1 receptor agonist.

Full text available for free download.

 ©Prescrire 1 May 2020

"Dulaglutide and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality" Prescrire Int 2020; 29 (215): 134. (Pdf, free).

Share Share on Facebook Share on Twitter